Prevalence of antinuclear antibodies in inflammatory bowel disease and seroconversion after biological therapy

Background: Estimates of detectable antinuclear antibodies (ANA) prevalence vary widely, from 6% in healthy populations to 50–80% in patients with autoimmune disease. However, there is a lack of evidence about the overall prevalence in inflammatory bowel disease (IBD) and ANA seroconversion after the beginning of biological therapy. Objectives: The aim of the study was to investigate the overall prevalence of ANA in IBD patients, their relationship with different treatments, clinical outcomes and the seroconversion rate of ANA in patients treated with biological therapy. Methods: Ambispective observational study including all consecutive IBD patients was carried out. Information about the presence of ANA, disease phenotype, duration, activity, complications, and past and current treatments were transversally collected. Retrospectively, in patients with detectable ANA, data regarding previous ANA detection and the diagnosis of lupus-like syndrome (LLS) was gathered. Results: A total of 879 IBD patients were included. We observed a detectable ANA prevalence of 13.6%. The presence of ANA was frequently associated with biological therapy (36/118) and decreased when immunomodulators were combined to this therapy (7/32). Of 78 patients with ANA prior to the beginning of biological therapy, a seroconversion rate of 28.8% was observed after a mean of 3.14 years. Only 1 patient suffered LLS. Conclusion: Our study showed a prevalence of detectable ANA higher than the expected in healthy population. The presence of ANA was lower when immunomodulator therapy is associated. The ANA seroconversion rate is relevant after the initiation of biological treatment nevertheless, the risk of LLS appeared to be marginal.

• Publication year

  2022

• Venue

  Therapeutic Advances in Gastroenterology

• Publication date

  2022-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/17562848221077837PMID 35251307PMCID 8894967
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Extraintestinal complications of inflammatory bowel diseases.

  2021cited by this paper
• Epidemiological survey of antinuclear antibodies in healthy population and analysis of clinical characteristics of positive population

  2019cited by this paper
• Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.

  2019cited by this paper
• Antinuclear Antibodies and Lupus-like Manifestations in Rheumatoid Arthritis and Ankylosing Spondylitis Patients at 4 Months' Follow-up After Treatment with Infliximab and Etanercept

  2019cited by this paper
• 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus

  2019cited by this paper
• Evaluation of Serum Calprotectin Level and Disease Activity in Patients with Rheumatoid Arthritis.

  2019cited by this paper
• Paradoxical Arthritis in Inflammatory Bowel Diasease Patients on Ustekinumab Treatment.

  2019cited by this paper
• Lupus-like reactions in patients with inflammatory bowel disease treated with anti-TNFs are insidious adverse events: data from a large single-center cohort

  2019cited by this paper
• European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus: the laboratory immunologist’s point of view

  2019cited by this paper
• Prescription medication use and antinuclear antibodies in the United States, 1999-2004.

  2018cited by this paper
• Combination Immunosuppression in IBD.

  2018cited by this paper
• Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta‐Regression of Diagnostic Data

  2018cited by this paper
• Autoantibodies Associated With Connective Tissue Diseases: What Meaning for Clinicians?

  2018cited by this paper
• Adverse events in IBD therapy: the 2018 update

  2018cited by this paper
• Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn’s disease-associated spondyloarthropathy

  2018cited by this paper
• Title Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns ( ICAP ) 2014-2015

  2018cited by this paper
• Antinuclear antibodies in the general population: positive association with inflammatory and vascular biomarkers but not traditional cardiovascular risk factors.

  2018cited by this paper
• Drug-induced lupus: Traditional and new concepts.

  2018cited by this paper
• Antinuclear antibodies and cancer: A literature review.

  2018cited by this paper
• Prevalence of antinuclear antibodies in hidradenitis suppurativa

  2018cited by this paper
• Antinuclear Antibodies: Marker of Diagnosis and Evolution in Autoimmune Diseases

  2018cited by this paper
• 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1 Diagnosis and Medical Management

  2017cited by this paper
• Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders.

  2017cited by this paper
• No evidence for induction of autoantibodies or autoimmunity during treatment of psoriasis with ustekinumab

  2017cited by this paper
• Serology in autoimmune hepatitis: A clinical-practice approach.

  2017cited by this paper
• Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management.

  2017cited by this paper
• The Relevance of Vitamin D and Antinuclear Antibodies in Patients with Inflammatory Bowel Disease Under Anti-TNF Treatment: A Prospective Study

  2016cited by this paper
• Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

  2016cited by this paper
• Prevalence of antinuclear antibodies in healthy Lebanese subjects, 2008–2015: a cross-sectional study involving 10,814 subjects

  2016cited by this paper
• Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014–2015

  2015cited by this paper
• Extraintestinal Manifestations of Inflammatory Bowel Disease

  2015cited by this paper
• Relationship between certain T helper cytokines and ANA staining: who is the helper?

  2015cited by this paper
• EASL Clinical Practice Guidelines: Autoimmune hepatitis.

  2015cited by this paper
• Have Biologics Changed the Natural History of Crohn's Disease?

  2014cited by this paper
• Frequency and specificity of antibodies against nuclear and cytoplasmic antigens in healthy individuals by classic and new methods

  2013cited by this paper
• The Incidence and Predictors of Lupus-like Reaction in Patients with IBD Treated with Anti-TNF Therapies

  2013cited by this paper
• Paradoxical inflammation induced by anti-TNF agents in patients with IBD

  2012cited by this paper
• Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

  2012cited by this paper
• Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages.

  2011cited by this paper
• Anti‐nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus‐like reactions from infliximab or adalimumab

  2011cited by this paper
• Formation of antinuclear and double‐strand DNA antibodies and frequency of lupus‐like syndrome in anti‐TNF‐&agr; antibody‐treated patients with inflammatory bowel disease

  2011cited by this paper
• The other side of immunoglobulin G: suppressor of inflammation

  2009cited by this paper
• Antinuclear antibodies and their detection methods in diagnosis of connective tissue diseases: a journey revisited

  2009cited by this paper
• Prevalence of Antinuclear Antibodies in 3 Groups of Healthy Individuals: Blood Donors, Hospital Personnel, and Relatives of Patients With Autoimmune Diseases

  2009cited by this paper
• Correlation Between Clinical Activity and Serological Markers in a Wide Cohort of Patients with Systemic Lupus Erythematosus

  2009cited by this paper
• The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

  2008cited by this paper
• Antinuclear antibodies: A marker associated with steroid dependence in patients with ulcerative colitis

  2008cited by this paper
• The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies

  2007cited by this paper
• Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies

  2007cited by this paper
• The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications

  2006cited by this paper
• Extraintestinal manifestations of inflammatory bowel disease.

  2005cited by this paper
• Infliximab Treatment Does Not Induce Organ‐specific or Nonorgan‐specific Autoantibodies Other than Antinuclear and Anti‐Double‐Stranded DNA Autoantibodies in Crohn's Disease

  2005cited by this paper
• Antinuclear antibody-negative lupus as a distinct diagnostic entity--does it no longer exist?

  2004cited by this paper
• CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes.

  2003cited by this paper
• The Prevalence and Significance of Positive Antinuclear Antibodies in Patients with Fibromyalgia Syndrome: 2–4 Years’ Follow-up

  2002cited by this paper
• The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study

  2001cited by this paper
• Immunoglobulins and IgG subclasses in patients with inflammatory bowel disease.

  1999cited by this paper
• Antinuclear Autoantibodies in Patients with Inflammatory Bowel Disease (High Prevalence in First-Degree Relatives)

  1997cited by this paper
• Protein metabolism in inflammatory bowel disease.

  1986cited by this paper
• Antibodies to the cytoskeleton components and other autoantibodies in inflammatory bowel disease.

  1985cited by this paper
• European Association for the Study of the Liver

  1971cited by this paper
• Chloroquine: Mode of Action

  1966cited by this paper

• Autoimmunity and Periodontitis.

  2026cites this paper
• Antinuclear Antibodies in Non-Rheumatic Diseases

  2025cites this paper
• SARS-CoV-2 Variant-Specific Antibodies in Vaccinated Inflammatory Bowel Disease Patients

  2025cites this paper
• Prevalence and association testing of antinuclear antibodies and inflammatory bowel disease in Taiwan

  2025influential citation
• Case 35-2023: A 38-Year-Old Woman with Waxing and Waning Pulmonary Nodules.

  2023cites this paper